Business Wire

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Applied in Xiaomi Yeelight’s Smart Lamp

Jaa

Seoul Semiconductor, a global innovator of LED products and technology, announces that its SunLike Series natural spectrum LEDs, which implement light that closely matches the spectrum of natural sunlight, continues to expand its global application base. Seoul Semiconductor announced that Yeelight, a leader in the intelligent lighting industry and part of Xiaomi’s ecosystem, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs as a light source for its Yeelight LED Desklamp Pro, a lamp that provides adjustable control of study hours, light colors and brightness control (dimming) via its smartphone application, and is compatible with both Amazon Alexa and Google Assistant applications.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180314005383/en/

Yeelight LED Desklamp Pro features Seoul Semiconductor's SunLike Series natural spectrum LED technol ...

Yeelight LED Desklamp Pro features Seoul Semiconductor's SunLike Series natural spectrum LED technology. (Photo: Business Wire)

Yeelight’s LED Desklap Pro was designed for an ambitious launch into the global smart desk lamp industry by the company, which has a management philosophy of innovating lighting interaction to deliver the most comfortable light through superior technology. Combining Yeelight’s state-of-the-art application control system and Seoul Semiconductor’s SunLike natural spectrum LED technology, consumers can experience light that closely matches the spectrum of natural sunlight.

Yeelight’s LED Desklamp Pro features user-controllable light modes for intensive studying, as well for vision protection. Equipped with Yeelight's scientific vision protection and study time setting programs, the lamps enable consumers to control these settings through a dedicated mobile phone application, and supports major smart home systems, such as Amazon Alexa and Google Assistant.

Through the use of a pulse width modulation (PWM) filter circuit for the analog signal module, the Desklamp Pro effectively controls light flickering, which relieves eye fatigue and may reduce the incidence of myopia (near-sightedness), which occurs more frequently in children who are not exposed to sunlight for extended periods of time.

Yeelight CEO Jiang Zhaoning, explained, "Yeelight has been leading the market by actively developing innovative lighting systems in partnership with leading partners around the world to provide the most comfortable and relaxing lighting products to consumers. We strive to provide consumers with the safest and healthiest light by working together with Seoul Semiconductor, the innovator of SunLike LED technology, which implements light that closely matches the spectrum of natural sunlight. We believe that thousands of people will experience this differentiated light source with the Smart Desklamp Pro that combines these two companies’ leading technologies."

Caleb Won, executive VP of global marketing group at Seoul Semiconductor, said, “Conventional LED desk lamps currently being used in homes can have potentially negative effects on children's eye health through prolonged exposure to excessive amounts of blue light at certain wavelengths. SunLike Series natural spectrum LEDs represent the next generation natural light LED technology that has achieved the highest level of eye safety certification from the International Commission on Illumination, recognizing SunLike LEDs as an RG-1 level light source with no photo-biological risks. While various attempts have been made to reduce blue light to protect eyesight (such as installing a lens cover), they did not provide a fundamental solution. By implementing light that closely matches the spectrum of natural sunlight, SunLike Series LEDs are an ideal solution to enhance children's eye health and contribute to an optimal learning environment."

Prolonged exposure to excessive blue light can disrupt sleep patterns and has the potential to negatively effect eyesight, because the retinal cell that detect light in the blue wavelength comprise only 5.7% of all human retinal cells. SunLike LED technology, however, implements light with a spectrum that closely matches natural sunlight, providing children with the healthiest and most comfortable light, improving their environment for learning, reducing eye fatigue, and displaying colors and textures more accurately.

SunLike Series natural spectrum LEDs were co-developed by Seoul Semiconductor and Toshiba Materials. They combine Seoul Semiconductor’s optical semiconductor technology and Toshiba Materials’ TRI-R Technology that produces light closer to the spectrum of natural sunlight.

About TRI-R technology

TRI-R® is a natural light LED source technology that reproduces the spectrum of natural sunlight, developed by the concept and spectrum technology of natural light. TRI-R is a registered trademark of Toshiba Material Co., Ltd.

About Yeelight

Yeelight, incubated by SOSVenture and made part of Xiaomi ecosystem in 2014, is an innovative leader dedicated to smart lighting applications. Working actively with Amazon, Google and Microsoft, Yeelight delivers the best lighting experience for a smart home.

Under the brands Xiaomi and Yeelight, Yeelight has produced dozens of smart lighting products, with more than 3 million connected lighting products shipped around the world. Yeelight works actively to integrate cutting-edge technology with distinctive designs. Their products incorporate the latest technologies, including AI ready, Wi-Fi enabled, and remote control to enable multiple smart features in the home.

Yeelight products have won international design awards, recognized with the IF Design Award 2017, Reddot Award 2017, IF Gold Design Award, and Good Design Award.

For more information about Yeelight, please visit www.yeelight.com.

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – the world’s smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC.

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

# Trademarks

WICOP and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

Contact information

Europe
Seoul Semiconductor Europe GmbH
Ariane Heim
Tel: +49-(0)89-450-3690-0
Email: press.eu@seoulsemicon.com
or
North America
Seoul Semiconductor Inc.
Andrew Smith
Tel: +1 (901) 831-6614
Email: andrew.smith@seoulsemicon.com
or
Asia
Seoul Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email: pr@seoulsemicon.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 05:53Tiedote

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 12:00Tiedote

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 10:00Tiedote

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme